KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 38.81%.

  • Pfizer's EBITDA Margin rose 33100.0% to 38.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.55%, marking a year-over-year increase of 507000.0%. This contributed to the annual value of 27.98% for FY2024, which is 175600.0% up from last year.
  • According to the latest figures from Q3 2025, Pfizer's EBITDA Margin is 38.81%, which was up 33100.0% from 34.48% recorded in Q2 2025.
  • In the past 5 years, Pfizer's EBITDA Margin registered a high of 47.01% during Q3 2022, and its lowest value of 410.16% during Q4 2023.
  • For the 5-year period, Pfizer's EBITDA Margin averaged around 22.31%, with its median value being 35.6% (2021).
  • As far as peak fluctuations go, Pfizer's EBITDA Margin tumbled by -2380700bps in 2023, and later surged by 2331600bps in 2024.
  • Over the past 5 years, Pfizer's EBITDA Margin (Quarter) stood at 32.77% in 2021, then surged by 39bps to 45.45% in 2022, then tumbled by -1002bps to 410.16% in 2023, then surged by 109bps to 35.5% in 2024, then grew by 9bps to 38.81% in 2025.
  • Its EBITDA Margin stands at 38.81% for Q3 2025, versus 34.48% for Q2 2025 and 36.15% for Q1 2025.